Novel Therapies for HDL Cholesterol
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Will novel HDL cholesterol therapies reduce cardiovascular risk? Dr. Robert Rosenson will discuss the hope for CETP inhibitors and HDL mimetics to modify HDL cholesterol and coronary heart disease risk.
Overview
Will novel HDL cholesterol therapies reduce cardiovascular risk? Dr. Robert Rosenson will discuss the hope for CETP inhibitors and HDL mimetics to modify HDL cholesterol and coronary heart disease risk.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
FCS and SHTG: Are We Meeting the Need?
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?